ORIGINAL RESEARCH article

Front. Immunol.

Sec. Inflammation

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1571120

This article is part of the Research TopicCrosstalk: Skin Cells and Immune Cells in Inflammatory Skin Diseases: Volume 2View all 4 articles

Oncostatin M Enhances the Lengthening of Sensory Nerves and Skin Hypersensitivity

Provisionally accepted
Chie  IshikawaChie Ishikawa1Ryo  SaitoRyo Saito1Masataka  SuehiroMasataka Suehiro1Kaori  IshiiKaori Ishii1Yuhki  YanaseYuhki Yanase2Tomoko  KawaguchiTomoko Kawaguchi1Kazue  UchidaKazue Uchida1Nozomi  YanagidaNozomi Yanagida1Tomofumi  NumataTomofumi Numata1Wataru  SasakiWataru Sasaki1Rina  KamigakiRina Kamigaki1Sachio  TakenoSachio Takeno3Akio  TanakaAkio Tanaka1*
  • 1Department of Dermatology, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
  • 2Department of Pharmacotherapy, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Hiroshima, Japan
  • 3Department of Otorhinolaryngology, Head and Neck Surgery, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan

The final, formatted version of the article will be published soon.

Background: Oncostatin M (OSM) is a cytokine that mediates inflammatory processes and is overexpressed in skin lesions of atopic dermatitis (AD). By amplifying neural responses to chemicals such as histamine, OSM increases sensitivity to pruritus. However, the morphological effects of OSM on peripheral sensory nerves and their subsequent impact on pruritus remain unclear. This study investigated OSM-induced peripheral nerve elongation, which may contribute to skin hypersensitivity.We assessed neurite outgrowth using primary mouse dorsal root ganglion (DRG) cells treated with OSM, IL-31, or nerve growth factor. Next, we pre-treated the cells with inhibitors of downstream signaling pathways of OSM, including extracellular signal-regulated kinase (ERK), signal transducers and activator of transcription (STAT) 3, c-Jun N-terminal kinase (JNK), and p38, followed by OSM administration to measure neurite outgrowth. Furthermore, OSM receptor βoverexpressing cell lines were established by gene transfer into the DRG cell line, and nerve elongation was measured after OSM administration. In vivo studies involved OSM administration in mouse skin models. Immunofluorescence staining was used to evaluate nerve elongation. We examined whether OSM-infused mice had increased hypersensitivity to mechanical stimuli-induced pruritus. Various cytokine stimuli were applied to CD4+ T cells isolated from healthy humans to examine the conditions under which OSM production increases.Results: OSM significantly induced neurite outgrowth in DRG cells and the effect of OSM surpassed the effects of IL-31 and nerve growth factor. The neurite outgrowth effect of OSM involved the JAK/STAT3, MEK/ERK, and p38/MAPK pathways. Compared to control cells, DRG cell lines that overexpressed OSM receptor β showed significantly enhanced neurite outgrowth upon OSM treatment. In vivo, OSM treatment increased nerve elongation in the mouse dermis. Behavioral assays in mice showed that OSM administration increased sensitivity to mechanical stimuli. IL-4 and TNFα increased OSM production in CD4+ T cells.OSM induces neurite elongation and may contribute to skin hypersensitivity. This suggests the potential utilization of OSM as a therapeutic target for inflammatory skin diseases such as AD.

Keywords: atopic dermatitis, Nerve elongation, Oncostatin M, Pruritus, Sensory nerve, itch

Received: 06 Feb 2025; Accepted: 23 Jun 2025.

Copyright: © 2025 Ishikawa, Saito, Suehiro, Ishii, Yanase, Kawaguchi, Uchida, Yanagida, Numata, Sasaki, Kamigaki, Takeno and Tanaka. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Akio Tanaka, Department of Dermatology, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.